Histones |
Anti-histone antibodies |
Prevents lung inflammation and damage induced by histones |
Ashar et al. (161) |
NETosis |
Cl-amidine
Tetrahydroisoquinolines (both tested on NETosis, effect on IAV yet to be determined)
|
Prevents lung injury mediated by NET |
Kusunoki et al. (164)
Martinez et al. (163)
|
ILC2 |
To be determined |
Promotes airway epithelium repair |
Califano et al. (171) |
Nox2 |
Cholestanol-conjugated gp91ds-TAT
Apocynin [also as reactive oxygen species (ROS) scavenger]
Ebselen (also as ROS scavenger and glutathione peroxidase mimetic)
|
Inhibits Nox2 activity |
To et al. (177)
Ye et al. (154)
Oostwoud et al. (184)
|
Tumor necrosis factor (TNF) |
Etanercept |
Prevents TNF-mediated lung injury and edema |
Shi et al. (205) |
IL-6 |
Administration of IL-6 |
Inhibits cell death of neutrophils; limits CD8+ T-cell-induced lung injury |
Dienz et al. (206); Pyle et al. (208) |
IL-27 |
Administration of IL-27 at recovery phase (5–10 days post-infection) |
Promotes recovery and improves lung immunopathology |
Liu et al. (214) |
Type III IFN |
Administration of type III IFN |
Controls IAV replication by type III IFN signaling pathways |
Davidson et al. (222); Kim et al. (224) |
PGE2 signaling |
AH6809 (EP2 antagonist)
GW627368X (EP4 antagonist)
|
Restores type I IFNs induction which are suppressed by PGE2 in macrophages |
Coulombe et al. (231) |
TLR4 signaling |
TLR4 antagonists (a. Eritoran and b. FP7) |
Ameliorates TLR4-mediated lung injury |
Shirey et al. (248)
Perrin-Cocon et al. (249)
|
TIRAP antagonism |
Peptide 2R9 |
Inhibits multiple TLR signaling |
Piao et al. (250) |
TLR2 signaling |
Anti-TLR2 antibody |
Inhibits TLR2 signaling mediated lethality |
Shirey et al. (251) |
TLR3 signaling |
Polysaccharides isolated from R. isatidis
|
Down regulates TLR3 expression to inhibit hypercytokinemia |
Li et al. (255) |
TLR7 signaling |
MENK |
Down regulates TLR7 expression and reduces lung pathology |
Tian et al. (256) |